Related Experiment Video

Updated: Aug 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 31, 2013

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

Tom Powles1, Kate Smith1, Arnulf Stenzl2

  • 1Barts Cancer Institute, London, UK.

European Urology
|April 18, 2017
PubMed

Insights

Immune checkpoint inhibitors show promise for metastatic urothelial cancer. New predictive biomarkers beyond PD-L1 are crucial for effective treatment selection.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Metastatic urothelial cancer (mUC) treatment landscape is evolving with immune checkpoint inhibitors (ICIs).
  • Phase 2 and 3 trials support ICIs as a viable therapeutic option for mUC.

Discussion:

  • Current predictive biomarkers for ICI efficacy in mUC are insufficient.
  • Programmed death-ligand 1 (PD-L1) expression shows inconsistent results, necessitating alternative biomarkers.

Key Insights:

  • ICIs represent a significant advancement in treating metastatic urothelial cancer.
  • The need for reliable predictive biomarkers is paramount for optimizing ICI therapy.

Outlook:

  • Future research should focus on identifying novel biomarkers for ICI response in mUC.
  • Development of robust biomarkers will improve patient stratification and treatment outcomes.

More Related Videos

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.